{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=17", "query": { "condition": "Normal Pregnancy", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 1974, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T12:12:37.928Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05938478", "title": "Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis", "Eczema" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 900, "start_date": "2022-12-08", "completion_date": "2035-09-30", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05938478" }, { "nct_id": "NCT00003425", "title": "Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Kentucky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "14 Years to 70 Years" }, "enrollment_count": 25, "start_date": "1997-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-26", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 4, "location_summary": "Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003425" }, { "nct_id": "NCT03896750", "title": "Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment", "Tuberculosis" ], "interventions": [ { "name": "PA-824", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 12, "start_date": "2024-04-17", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 3, "location_summary": "Miami, Florida • St Louis, Missouri • Knoxville, Tennessee", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896750" }, { "nct_id": "NCT02512835", "title": "Understanding the Value of Community Vital Signs in Primary Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colon Cancer", "Breast Cancer", "Cervical Cancer", "Prostate Cancer", "Cardiovascular Disease" ], "interventions": [ { "name": "Community vital signs", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 120, "start_date": "2015-10", "completion_date": "2016-11-01", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 2, "location_summary": "Fairfax, Virginia • Richmond, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02512835" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT00513591", "title": "Duke Autoimmunity in Pregnancy Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnancy", "Systemic Lupus Erythematosus", "Cutaneous Lupus", "Rheumatoid Arthritis", "Sjogren's Syndrome", "Scleroderma" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 513, "start_date": "2007-08", "completion_date": "2018-11-19", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513591" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT04846959", "title": "Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 818, "start_date": "2021-07-30", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 2, "location_summary": "Morrisville, North Carolina • Wilmington, North Carolina", "locations": [ { "city": "Morrisville", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04846959" }, { "nct_id": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Pancreatic Cancer", "Lung Cancer", "Head and Neck Cancer", "Breast Cancer", "Kidney Cancer", "Colorectal Cancer", "Bladder Cancer", "Ovarian Cancer", "Sarcoma", "Gallbladder Cancer", "Bile Duct Cancer", "Esophageal Cancer", "Uterine Cancer", "Cholangiocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-09-29", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-24T12:12:37.928Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383210" } ] }